OrthoPediatrics (NASDAQ:KIDS) Shares Gap Up on Analyst Upgrade

OrthoPediatrics Corp. (NASDAQ:KIDS)’s stock price gapped up prior to trading on Tuesday after Needham & Company LLC raised their price target on the stock from $37.00 to $42.00. The stock had previously closed at $33.60, but opened at $35.00. Needham & Company LLC currently has a buy rating on the stock. OrthoPediatrics shares last traded at $35.44, with a volume of 160,769 shares.

A number of other equities research analysts have also recently weighed in on the company. JMP Securities restated a “market outperform” rating and set a $50.00 price objective on shares of OrthoPediatrics in a research note on Tuesday. Truist Financial cut shares of OrthoPediatrics from a “buy” rating to a “hold” rating and lowered their price target for the company from $39.00 to $31.00 in a report on Thursday, January 25th.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 3,213 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,646.67. Following the completion of the sale, the chief executive officer now directly owns 139,384 shares in the company, valued at $3,845,604.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CFO Fred Hite sold 3,195 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $88,150.05. Following the sale, the chief financial officer now directly owns 94,072 shares of the company’s stock, valued at $2,595,446.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David R. Bailey sold 3,213 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,646.67. Following the completion of the transaction, the chief executive officer now directly owns 139,384 shares in the company, valued at $3,845,604.56. The disclosure for this sale can be found here. Insiders sold 17,253 shares of company stock valued at $477,375 in the last quarter. 31.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KIDS. Prime Capital Investment Advisors LLC purchased a new stake in OrthoPediatrics in the fourth quarter valued at approximately $2,035,000. Vanguard Group Inc. increased its stake in shares of OrthoPediatrics by 1.3% in the third quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock worth $27,546,000 after acquiring an additional 10,861 shares during the period. Blue Trust Inc. boosted its holdings in OrthoPediatrics by 1.5% in the fourth quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock valued at $917,000 after purchasing an additional 421 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in OrthoPediatrics by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock valued at $3,895,000 after purchasing an additional 549 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its stake in shares of OrthoPediatrics by 24.0% during the 4th quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after buying an additional 8,770 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44. The firm has a market cap of $825.51 million, a PE ratio of -37.72 and a beta of 1.16. The stock has a 50 day simple moving average of $28.80 and a two-hundred day simple moving average of $29.04.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. The firm had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. Sell-side analysts expect that OrthoPediatrics Corp. will post -1.34 earnings per share for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.